The Hospital-Acquired Infection Diagnostics Market is projected to reach US$ 4.86 Billion by 2034 from US$ 4.48 Billion in 2025, registering a CAGR of 1.02% during 2026–2034. The market is expanding as hospitals and healthcare facilities strengthen infection prevention, surveillance, and diagnostic testing capabilities. Growing concerns surrounding healthcare-associated infections, antimicrobial resistance, patient safety, and the need for faster identification of infectious pathogens are supporting continued demand for diagnostic technologies.
What is driving the market?
The increasing focus on infection prevention, rising antimicrobial resistance, and the need for rapid and accurate pathogen identification are key market drivers. Hospital-acquired infections can increase treatment complexity, lengthen hospital stays, and place additional pressure on healthcare resources. Consequently, hospitals are increasingly emphasizing early detection and appropriate treatment through reliable microbiological and molecular diagnostic testing.
Traditional culture-based methods remain important, but their longer turnaround times have encouraged interest in molecular diagnostics and other rapid testing technologies. PCR-based assays, automated microbiology systems, immunoassays, and multiplex diagnostic platforms can help identify pathogens and resistance-related characteristics more efficiently in appropriate clinical settings.
The growing threat of antimicrobial resistance is further increasing the importance of diagnostic testing. Rapid identification of pathogens and antimicrobial susceptibility information can support more targeted treatment decisions and antimicrobial stewardship programs. This is encouraging healthcare facilities to invest in diagnostic platforms capable of providing clinically useful information within shorter timeframes.
Download Sample PDF: https://www.theinsightpartners.com/sample/TIPRE00004163
Which region leads?
North America represents a major regional market for hospital-acquired infection diagnostics, supported by advanced laboratory infrastructure, strong infection-control programs, and widespread adoption of molecular and automated diagnostic technologies. Hospitals and healthcare networks in the region increasingly prioritize surveillance, rapid testing, antimicrobial stewardship, and laboratory automation.
The presence of established diagnostic manufacturers and healthcare systems also supports the adoption of advanced testing platforms. Investments in laboratory automation and rapid molecular diagnostics are helping healthcare providers improve testing efficiency and manage infectious disease risks.
Europe remains an important market, supported by established healthcare systems, infection-prevention initiatives, and increasing attention to antimicrobial resistance. Asia Pacific offers substantial growth opportunities as hospital infrastructure expands, healthcare expenditure increases, and diagnostic capabilities improve. China and India, in particular, provide opportunities as hospitals modernize laboratories and strengthen infection-control programs.
Which segment leads?
Molecular diagnostic technologies represent an important segment of the hospital-acquired infection diagnostics landscape because of their ability to rapidly identify infectious organisms and clinically relevant targets. Molecular platforms can support detection of bacterial, viral, and fungal pathogens and, depending on the assay, identify specific antimicrobial-resistance markers.
PCR-based testing and multiplex diagnostic platforms are gaining attention because they can simultaneously evaluate multiple targets. This can be particularly useful when patients present with symptoms that may be associated with more than one potential pathogen.
Automated microbiology and culture-based diagnostics remain important components of hospital laboratories. While molecular technologies can provide rapid results, conventional culture and antimicrobial susceptibility testing continue to play an important role in identifying organisms and guiding treatment decisions.
The market is therefore characterized by increasing integration of different diagnostic technologies rather than the complete replacement of conventional methods. Hospitals may combine molecular assays, culture systems, immunoassays, and automated laboratory platforms according to clinical requirements and available resources.
Which companies are prominent?
The report identifies bioMérieux, Abbott Laboratories, Alere, Inc., Roche AG, Siemens Healthcare, Becton Dickinson, Cepheid Inc., Thermo Fisher Scientific, Seegene, Inc., and QIAGEN as prominent market participants.
These companies compete across molecular diagnostics, microbiology systems, pathogen detection, automated laboratory technologies, immunoassays, and infectious-disease testing solutions. Competitive differentiation increasingly depends on diagnostic accuracy, turnaround time, automation, multiplexing capabilities, workflow efficiency, and compatibility with hospital laboratory infrastructure.
The competitive environment is also influenced by the increasing integration of diagnostic platforms into broader laboratory information systems. Hospitals seek technologies that can improve sample processing, reduce manual intervention, support traceability, and deliver actionable results efficiently.
What is changing in 2026?
The market is shifting toward faster, automated, and increasingly molecular approaches to hospital-acquired infection detection. Healthcare providers are placing greater emphasis on shortening diagnostic turnaround times while maintaining reliable pathogen identification and supporting appropriate antimicrobial treatment.
Multiplex testing is becoming increasingly relevant because patients with suspected healthcare-associated infections may require evaluation for multiple organisms. Platforms capable of testing several targets from a single specimen can potentially streamline diagnostic workflows and support faster clinical decision-making.
Artificial intelligence, laboratory automation, and digital connectivity are also influencing diagnostic workflows. Automated systems can help laboratories process increasing sample volumes while reducing repetitive manual tasks. Integration with laboratory information systems can further improve result management and data availability.
Another important trend is the growing connection between diagnostics and antimicrobial stewardship. Rapid diagnostic information can support healthcare teams in moving from broad empirical treatment toward more targeted therapy when clinically appropriate, potentially improving antimicrobial-use practices.
Purchase a Copy of this report: https://www.theinsightpartners.com/buy/TIPRE00004163
What are the major investment opportunities?
The strongest opportunities lie in rapid molecular diagnostics, multiplex pathogen detection, antimicrobial-resistance testing, automated microbiology, and integrated hospital laboratory systems. Demand for faster diagnostic information creates opportunities for technologies capable of identifying pathogens while maintaining high analytical performance.
Investment in point-of-care and near-patient diagnostic technologies also presents opportunities where rapid results can support timely clinical decisions. Similarly, automated laboratory platforms can help hospitals address growing testing volumes and workforce-related constraints.
Another important opportunity is antimicrobial-resistance diagnostics. Technologies that can rapidly detect resistance-associated markers or provide actionable susceptibility information can support antimicrobial stewardship and infection-control programs.
Asia Pacific offers additional expansion potential as hospitals upgrade diagnostic infrastructure and increase access to advanced laboratory technologies. Manufacturers can pursue opportunities through partnerships with healthcare providers, regional distributors, laboratory networks, and public-health organizations.
Also Available in: Korean | German | Japanese | French | Chinese | Italian | Spanish
Related Reports:
Technetium-99m Market Share, Demand & Forecast 2031
Recombinant Albumin Market Trends & Forecast 2031
About Us
The Insight Partners is a one-stop provider of actionable industry research and intelligence. We help our clients get solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Healthcare IT, Manufacturing and Construction, Medical Devices, Technology, Media and Telecommunications, Food and Beverages, Consumer Goods, and Chemicals and Materials.
Contact Us
Contact Person: Ankit Mathur
Phone: +1-646-491-9876
E-mail : sales@theinsightpartners.com
